Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer

Colorectal Cancer Clinical Trial

Official title:

Phase II Study Of Colorectal ACF Screening, Regression And Prevention In High Risk Participants

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00062023
• Other study ID #: ID01-454
• Secondary ID: P30CA016672MDA-I
• Status: Terminated
• Phase: Phase 2
• First received: June 5, 2003
• Last updated: July 27, 2012
• Start date: June 2003
• Est. completion date: May 2006

Study information

• Verified date: July 2012
• Source: M.D. Anderson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether sulindac, aspirin, or ursodiol is more effective in preventing colorectal cancer.

PURPOSE: This randomized phase II trial is studying how well sulindac works compared to aspirin or ursodiol in preventing colorectal cancer.

Description:

OBJECTIVES:

• Determine the percentage change in colorectal aberrant crypt foci (ACF) in patients with a history of colorectal cancer or at high risk for colorectal cancer when treated with sulindac vs aspirin vs ursodiol.

• Determine the safety and efficacy of these drugs, in terms of ability to cause regression of existing colorectal ACF and prevent new ACF development, in these patients.

OUTLINE: This is a partially blinded, randomized, placebo-controlled study. Patients are stratified according to colorectal neoplasia (adenoma vs carcinoma). Patients are randomized to 1 of 4 treatment arms.

• Arm I: Patients receive oral sulindac twice daily.

• Arm II: Patients receive oral aspirin once daily.

• Arm III: Patients receive oral ursodiol three times daily.

• Arm IV: Patients receive oral sulindac placebo twice daily. In all arms, treatment continues for 12 months in the absence of disease progression or unacceptable toxicity.

Patients undergo a colonoscopy at baseline and at the end of treatment.

Patients are followed at 2 months after the end of treatment.

PROJECTED ACCRUAL: A total of 172 patients (43 per treatment arm) with a history of colorectal cancer or adenomas will be accrued for this study. A total of 20 additional patients with no elevated risk of colorectal neoplasia will be accrued, but not randomized, for this study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: May 2006
• Est. primary completion date: April 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Male or female subjects, age 40-80 years

2. with >5 colorectal ACF and a prior history of colorectal cancer defined as Dukes A/B1 carcinoma within 5 years of entry or any stage of colorectal cancer if at least 5 years post surgical resection (86 subjects)

3. with >5 colorectal ACF and recent/current history of colorectal adenoma(s) defined as one of the following: one adenomatous polyp >1cm or two or more adenomatous polyps of any size or one adenomatous polyp of any size and a documented history of adenomatous polyp(s) (86 subjects)

4. No elevated risk of colorectal cancer or adenomas (20 subjects)

5. Subjects will be permitted to use Nasonex but all other nasal steroids are prohibited. Subjects may change to Nasonex but must have discontinued previous nasal steroid use for at least 30 days prior to study randomization.

6. If participant is female and of childbearing potential, she must agree to use adequate contraception and must have a negative serum pregnancy test within 14 days prior to study drug administration

7. No use of investigational agent(s) within the last 3 months or at the discretion of the medical monitor

8. The subject will be allowed to proceed to randomization so long as all of the following laboratory criteria are met on baseline evaluation: Hgb > 10.0 g/dl, platelet count > 100,000/ul; WBC > 3,000/ul; ALT < 2 x upper limit of normal; AST < 2 x upper limit of normal, and total bilirubin <1.5mg/100ml.

9. Patients requiring use of hormone modulators such as Tamoxifen or Arimidex will be permitted to enroll providing they meet all of the eligibility criteria noted above

Exclusion Criteria:

1. Known diagnosis of FAP, hereditary non-polyposis colon cancer (HNPCC), or inflammatory bowel disease

2. History of hypersensitivity to COX-2 inhibitors, sulfonamides, NSAIDs , salicylates, or ursodeoxycholic acid

3. Use of NSAIDs, including aspirin, at any dose during the six months prior to study entry will require a three month washout period prior to eligibility beginning with the time of the last dose. Participants must be off all NSAIDs for three months prior to study entry. Individuals on cardioprotectant aspirin at any dose will not be eligible.

4. History of gastroduodenal ulcers documented endoscopically would preclude a patient from participation in the trial

5. Known inability to participate in the scheduled follow-up tests.

6. Significant medical or psychiatric problems which would make the patient a poor protocol candidate, in the opinion of the principal investigator.

7. "Unacceptable clinical risk" to proceed (based upon the subclinical discoveries made via baseline colonoscopy and biopsies).

8. Patient has undergone a total colectomy

9. Patient has received chemotherapy within the past 6 months of randomization into study. Topical chemotherapy will be assessed on a case-by-case basis. Any history of pelvic or rectal radiation therapy will exclude a patient from participating.

10. History of invasive carcinoma in the past five years (except patients with Dukes A/B1 carcinoma within 5 years of entry or any stage of colorectal cancer if at least 5 years post surgical resection)

11. Patients with rectal cancer are excluded except for transanal excision without radiation.

12. Patients with acute liver disease, unexplained transaminase elevations or a history of renal stones would be excluded.

13. Participants will not be permitted to be randomized into the trial if any of the following laboratory values are reported at baseline : Hgb < 10.0 g/dl, platelet count <100,000/ul; WBC < 3,000/ul; ALT > 2 x upper limit of normal; AST > 2 x upper limit of normal, and total bilirubin >1.5mg/100ml.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• Acetylsalicylic acid (Aspirin)
Patients receive oral aspirin once daily for 12 months.
• Sulindac
Patients receive oral sulindac twice daily for 12 months.
• Ursodiol
Patients receive oral ursodiol three times daily for 12 months.

Other:
• Sulindac Placebo
Oral sulindac placebo twice daily.

Locations

Country	Name	City	State
United States	M.D. Anderson Cancer Center at University of Texas	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage Change in Colorectal ACF Patients Treated with Sulindac, Aspirin or Ursodiol		12 Months	No

External Links

•   UT MD Anderson Cancer Center Website